Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 15/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.78 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.53 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82563 | 1.00 | NAMPT (0.78) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 | |
| Biphenyl SCHEMBL27464525 | 0.95 | NAMPT (0.77) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 | |
| SCHEMBL28376292 | 0.91 | NAMPT (0.82) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 | |
| SCHEMBL30292612 | 0.88 | NAMPT (0.72) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 | |
| SCHEMBL20095358 | 0.88 | NAMPT (0.72) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 | |
| SCHEMBL5470447 | 0.88 | NAMPT (0.72) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 | |
| SCHEMBL5470442 | 0.88 | NAMPT (0.72) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 | |
| Daporinad SCHEMBL31181445 | 0.88 | NAMPT (1.00) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 | |
| Daporinad SCHEMBL156944 | 0.88 | NAMPT (1.00) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 | |
| Daporinad SCHEMBL82367 | 0.88 | NAMPT (1.00) | NAMPTCYP3A4CYP2C9HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4607319-B2 | — | — | 2011-01-05 | — | — | JP | claimed |
| JP-4599062-B2 | — | — | 2010-12-15 | — | — | JP | claimed |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | claimed |
| EP-1487444-B9 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-07-21 | — | — | EP | claimed |
| US-20090325923-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | TOPOTARGET SWITZERLAND SA (CH) | 2009-12-31 | — | — | US | claimed |
| EP-1487444-B1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2009-12-30 | — | — | EP | claimed |
| WO-2009109610-A1 | USE OF NAD INFORMATION INHIBITORS FOR THE TREATMENT OF ISCHEMIA-REPERFUSION INJURY | TOPOTARGET SWITZERLAND S.A. (CH) | 2009-09-11 | — | — | WO | claimed |
| EP-2073808-A2 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | Topotarget Switzerland SA (CH) | 2009-07-01 | — | — | EP | claimed |
| WO-2008025857-A2 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | TOPOTARGET SWITZERLAND SA (CH) | 2008-03-06 | — | — | WO | claimed |
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | ASTELLAS PHARMA GMBH (DE) | 2007-09-20 | — | — | US | claimed |
| JP-2005528361-A | — | — | 2005-09-22 | — | — | JP | claimed |
| EP-1487444-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | Fujisawa Deutschland GmbH (DE) | 2004-12-22 | — | — | EP | claimed |
| CN-1152032-C | Pyridylalkane-and pyridylalkyne-acid amides as cytostatics and immunosuppressants | ���ָ���ҩ�ɷ�����˾ | 2004-06-02 | — | — | CN | claimed |
| US-20040009967-A1 | Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | KLINGE PHARMA GMBH | 2004-01-15 | — | — | US | claimed |
| WO-2003080054-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | FUJISAWA DEUTSCHLAND GMBH (DE) | 2003-10-02 | — | — | WO | claimed |
| EP-1348434-A1 | Use of pyridyl amides as inhibitors of angiogenesis | Fujisawa Deutschland GmbH (DE) | 2003-10-01 | — | — | EP | claimed |
| EP-0923570-B1 | PYRIDYL ALKENE- AND PYRIDYL ALKINE- ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | FUJISAWA DEUTSCHLAND GMBH (DE) | 2002-09-25 | — | — | EP | claimed |
| JP-2002512190-A | — | — | 2002-04-23 | — | — | JP | claimed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | claimed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | NFATC1, PDCD1, ACIN1 | NAMPT 122/4885CYP3A4 2342/4885CYP2C9 3940/4885 |
| US-20040009967-A1 | Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | IDO1, ALK, ARG1 | NAMPT 350/4885CYP3A4 1520/4885CYP2C9 2017/4885 |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | PNPO, NAMPT, NAPRT | NAMPT 2/4885CYP3A4 905/4885CYP2C9 810/4885 |
| US-20090325923-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | NAMPT, NNMT, NQO2 | NAMPT 1/4885CYP3A4 1914/4885CYP2C9 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.